Abstract
Remdesivir is one of the effective anti-viral drugs used as a Covid-19 therapy at moderate, severe and critical degrees. Side effects that need to be considered in the use of remdesivir is hepatotoxicity. The active metabolite of remdesivir (GS-44152) is thought to play a role in mitochondrial damage in liver cells, inhibiting bile acid transport, and inducing oxidative stress. This study was conducted to evaluate the use of remdesivir associated with changes in liver function SGOT and SGPT. This study was retrospective observation of moderate, severe and critical COVID-19 patients receiving remdesivir with inclusion criteria of all inpatient medical records at Bhayangkara Hospital Surabaya for the period of August 2020-July 2021. The results showed that significant increase of liver enzymes occurred in SGPT (Pre 29 .50; Post 33.50) while in SGOT (Pre 33.00; Post 26.00), enzymes were significantly decreased. The decrease was greater in the SGPT (Pre 69.00; Post 47.00) and SGOT (Pre 56.00; Post 32.00) hepatoprotector groups. The use of remdesivir had no effect on liver function as indicated by an increase in SGPT value and a decrease in SGOT value, both of which were still in the normal range.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
